What is HC Wainwright’s Forecast for AUTL FY2027 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Equities researchers at HC Wainwright raised their FY2027 earnings per share estimates for Autolus Therapeutics in a report released on Wednesday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.69) for the year, up from their prior estimate of ($0.74). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $41.24 million for the quarter, compared to the consensus estimate of $39.54 million. Autolus Therapeutics had a negative return on equity of 263.25% and a negative net margin of 186.37%. During the same quarter in the prior year, the business earned ($0.30) EPS.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. UBS Group reiterated a “buy” rating on shares of Autolus Therapeutics in a research note on Wednesday. Finally, Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.19 on Friday. Autolus Therapeutics has a 1 year low of $1.12 and a 1 year high of $2.58. The stock has a market capitalization of $316.94 million, a PE ratio of -1.23 and a beta of 2.32. The company has a debt-to-equity ratio of 5.25, a quick ratio of 4.40 and a current ratio of 3.72. The stock has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.66.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Syncona Portfolio Ltd purchased a new stake in Autolus Therapeutics during the 2nd quarter worth about $26,625,152. Alphabet Inc. acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth about $1,117,000. Cetera Investment Advisers increased its holdings in shares of Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after acquiring an additional 29,324 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after acquiring an additional 11,197 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after acquiring an additional 8,309 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.